'Lead Compound' Rule For Drug Patents Leads Courts Astray
In patent litigation involving most technologies, the procedure for invalidating a patent for obviousness under Title 35 of the U.S. Code, Section 103(a), is straightforward....To view the full article, register now.
Already a subscriber? Click here to view full article